{"id":966254,"date":"2026-05-21T18:28:12","date_gmt":"2026-05-21T22:28:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/"},"modified":"2026-05-21T18:28:12","modified_gmt":"2026-05-21T22:28:12","slug":"pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/","title":{"rendered":"Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095\u00a0<\/em><br \/>\n        <br \/>\n        <em>enrolling patients with ICI-refractory solid tumors<\/em>\n      <\/p>\n<p>SOUTH SAN FRANCISCO, Calif., May  21, 2026  (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.<\/p>\n<p>\n        <strong>Poster Presentation<\/strong>\n      <\/p>\n<p>\n        <strong>Title:<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7n4Ka6859iALwU6Mw1jh49LI_APJ74da7mXg_CS3hUOV1mdACR6SbwDHsc4e5rFvLDCFs2gDyErHwUBxV5nhSc5ryvTj1Cxvnig1auGiicMH1agZz8k_uOpv2FLebMdzPBNcuaciYoZp8W690Q_po0UftwoPpT89V0gbtF10FSpoTo_Z5odFEHukfNyB-nd3GPUWpMQQfO1n6e91K0rkHFUi0JV_UeO_JiowAsWNDEb7L5R8rV1qCv-UrnPcnFoh-6c0hmhN8wxLeyBgRBhwtgjnuiRuQWryz0OF8ZYerTQGjrqLkgaSJeVatqyj9mzMRkmxDLr38fWlm4w2ih_0uVISsfjm88Ic1PGuCodrX4hXRnk55hUelk25g8LyUgT9aWNh1JbAaseKnHdtxszxew==\" rel=\"nofollow\" target=\"_blank\">Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual \u03b1v\u03b28 \/\u03b1v\u03b21 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint Inhibitors<\/a>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:10%;width:10%;min-width:10%\">\n            <strong>Presenter:<\/strong>\n          <\/td>\n<td style=\"max-width:90%;width:90%;min-width:90%\">Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer Center<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Session:<\/strong>\n          <\/td>\n<td>Developmental Therapeutics \u2013 Immunotherapy<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Date:<\/strong>\n          <\/td>\n<td>Saturday, May 30, 2026, 1:30 \u2013 4:30 p.m. Central Time<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Location:<\/strong>\n          <\/td>\n<td>Hall A, Poster 467b<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong><br \/>\n          <br \/>FORTIFY &#8211; PLN-101095 Phase 1b Indication Expansion Trial<\/strong>\n      <\/p>\n<p>PLN-101095 is currently being evaluated in Phase 1a\/1b open-label, dose-escalation and indication expansion trial (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2nUMTeJU2uS1BK1K4leA3IIrjXaJ0e43MB-UEO-1exdKCChpcsxa4x0tKI_jNwGBN8U0xdv1SH7-6iY48VBiynfpQggI8kyUNcjQhx-SBSt3oua-Am_Tpg9rrPJ9H2T_\" rel=\"nofollow\" target=\"_blank\">NCT06270706<\/a>) to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with\u00a0pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Pliant is currently enrolling patients in FORTIFY, a Phase 1b open-label, indication expansion trial enrolling three cohorts of patients with non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden or clear cell renal cell carcinoma. Patients will be treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab will be added as combination therapy.<\/p>\n<p>\n        <strong>About Pliant Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant\u2019s lead program is PLN-101095, an oral, small molecule, dual-selective inhibitor of \u03b1<sub>v<\/sub>\u00df<sub>8<\/sub>\u00a0and \u03b1<sub>v<\/sub>\u00df<sub>1<\/sub>\u00a0integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant\u2019s preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes, and renal cells.<\/p>\n<p>For additional information on Pliant, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0LHPNldMeH5CExV_hTUuKRbjOZoRoc9ByUDEdPsuhsHd8JhLgjdL6TXP2008fVuMryZiGBEcKOx5BIBwnkVhuZZCmZXOwWttgkbuJp-dp8epWYemtWQbFAcv1ySQU8l7k7-tY8ROKdEnFAjppIQMh_EX2haYR7QLio_FSL8QisEOuZDXXKJhmDN7Kdp9t44mVNn6yq3MmDbQ6rJ0SMhTigBWLHwewslvus7ycXnrNMclCOKhB6f6hDXUBUyLNt9xJghx0GCsN_2HT_sRy_yX5Ikai-lAy-4-eO5VYOc__bwBHkeKO1nKssLNazYmZMee5K12ve-ZXOjylj4If5jlD5UvFIufkUxkfVynovwE_EgCdPnAcQkFJj-lQlGvJ566KTBrpoJqWw1jG8Ndh5U4ZO2n_mVVnn9fmjv9hW4jtHxCJqPoYE9GnphgD6vRWC3oyFfTtDvUA7T0OePYqvFN5FDtykkOzI2zeKOg2rIYVxI=\" rel=\"nofollow\" target=\"_blank\">www.PliantRx.com<\/a> and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oConL-4-Gx7eY7vJ2cwJHxS3CI5LhzORULLIlR-8pfdMzZ-79Nlayf6DWKeRgo9OjpMg1OVxBWcjoUsD-KzVVnYd3HL_-JPZ0S1C1K2r1_3ixDVyJTAW3rFUfi2hnioABsqCwNbmSUO8jNszdtqiL-qMZUpiw4VYNNHCR57xu2zVipfL8ZQA-IGELPFLgw6VQdSHsjOpWKMKJFIdgOHjJ7MJ_KKUEcFO3BVTN7QiXxNArsiZ5FytXqdxdpkPgFgdDEumqaFbVt4u8us83FgubIhz_RMz5yqdjJVa0dxsSfxFNHH0iW1ep9LUdt2-uK2UQcpMcDRO63hf7ptT5gRjAdW55jpgUYgCE_4Fw1rw3IH0-FzSjMamv13QtmjCJmGX\" rel=\"nofollow\" target=\"_blank\">X<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C5Q5ig1tfzFdCkrewSnVvdxqGv-LXJ0oT2y_2E3Gb-1VOMNOr6MbXp0dhdxqD7Dz6Rsu0qac3eXLpsFC3ZxU1phcd_9GM4sXOdngcF6O76GaHKzPiIP6UvjPIddvqo4LgNrsXd707w7c8tYWDjVlyLWLomMkkS72P2r_rk73GP3dcv-rQ2wBbNVoT9bGs-CZNsLkkJ4cUn9NKsnCIDtPj46EiR8F8lmHpFNHaizFipCy0Vbd5Qd1fZ2E0TmBftTts4lIeK7eUYh5YAPBF9AShVLs4cdG50e2aJLFFYWxZmzO_xqjLVGZz6iEOQdtl5ItDNWPrVNbmPGuhSzv6fm4TRURIG7GFde75RkniqjAhU3-p_V8tpLKrd44WHGb_quGc1M7JlCTrlsebmR0tr1pQsUYAAb5oOeMloefViNAH-hZHU73Kq59A2AGSfx-VkYw\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ceahoi3NwdXJDN2aBBWjKOjifviEM5A-Y-ASJBsT7BhAUo0gp55VcJhTN1eIz3EVJZjovQ5hnlZ9tO-qu0Lm_2n0kAMi1jxhiSG48Upws77wMbj1kB29H6N7oMX7aFZxP--7FJzF4zeVkK9Pt62X892styhCgEvgGfKbvsElliYqJNdv27K_ktwYbSYsExTgITQG5xSpqz5hVwmM2Usb_gr4SApWlw1VOLNT8moMx3TvPEWn2h3nze--c7AORWXR7dVO2RfhNa3DJ1ADx1kkFPWflNw0JzxaSconfBjSPeuNGMc1_n3BUtD_vFz8-sTHfkmK7_g761pkvmC2IcT80x0gvalFGvZi0VaiBgP_kBkWQE9-rePOjV24q-m7qxeNwFBRCk51hD7fmqMronN2tCs8ZD_M8KvUEgbUdNtiTJ6loI9BDyrYoOWhtgUezMGU\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>\n        <strong>Investor and Media Contact:<\/strong><br \/>\n        <br \/>Christopher Keenan<br \/>Vice President, Investor Relations and Corporate Communications<br \/>Pliant Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eJmiX59t0LL-y3z0yCUR2dXnAsVSLIbQ40hwKE2OCwfSLf_b4RTxesazBCT4Mrfxw-lq4j9QyeQDe61aDpTZip4jZTf8z3RadrrexlqONsecDbKufcQm_sJEUnqKH7bDuCx_HC5ciwb6Vw_u6Rc4tQtjdhai2iby4SwhoGNpEgdC6ueNWfWnnC4VxyLcPDALfZFBLhVPUv88HUs58bwShTG35gYMox0bslDmBk1RiN1-UXwVAXrOOlWlULSlMsw2j2Ha4H60GdytGuh2pXdBhA==\" rel=\"nofollow\" target=\"_blank\">ir@pliantrx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTA3MiM3NjE1MDc3IzIxODU0NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmQ5ODZmYjAtNDcxMi00ZTIyLWFiYmEtNzFiOTU5ODBhNTcxLTExOTcwMzAtMjAyNi0wNS0yMS1lbg==\/tiny\/Pliant-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095\u00a0 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026. Poster Presentation Title: Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual \u03b1v\u03b28 \/\u03b1v\u03b21 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint Inhibitors Presenter: Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer Center Session: Developmental Therapeutics \u2013 Immunotherapy Date: Saturday, May 30, 2026, 1:30 \u2013 4:30 p.m. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-966254","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095\u00a0 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026. Poster Presentation Title: Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual \u03b1v\u03b28 \/\u03b1v\u03b21 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint Inhibitors Presenter: Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer Center Session: Developmental Therapeutics \u2013 Immunotherapy Date: Saturday, May 30, 2026, 1:30 \u2013 4:30 p.m. &hellip; Continue reading &quot;Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-21T22:28:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTA3MiM3NjE1MDc3IzIxODU0NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting\",\"datePublished\":\"2026-05-21T22:28:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"wordCount\":396,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNTA3MiM3NjE1MDc3IzIxODU0NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\\\/\",\"name\":\"Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNTA3MiM3NjE1MDc3IzIxODU0NzY=\",\"datePublished\":\"2026-05-21T22:28:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNTA3MiM3NjE1MDc3IzIxODU0NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNTA3MiM3NjE1MDc3IzIxODU0NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - Market Newsdesk","og_description":"Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095\u00a0 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026. Poster Presentation Title: Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual \u03b1v\u03b28 \/\u03b1v\u03b21 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint Inhibitors Presenter: Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer Center Session: Developmental Therapeutics \u2013 Immunotherapy Date: Saturday, May 30, 2026, 1:30 \u2013 4:30 p.m. &hellip; Continue reading \"Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-21T22:28:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTA3MiM3NjE1MDc3IzIxODU0NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting","datePublished":"2026-05-21T22:28:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/"},"wordCount":396,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTA3MiM3NjE1MDc3IzIxODU0NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/","name":"Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTA3MiM3NjE1MDc3IzIxODU0NzY=","datePublished":"2026-05-21T22:28:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTA3MiM3NjE1MDc3IzIxODU0NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNTA3MiM3NjE1MDc3IzIxODU0NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=966254"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966254\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=966254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=966254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=966254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}